Dashboard
Manage Tickers

GMTXDisc Medicine, Inc.

Nasdaq geminitherapeutics.com


$ 29.75 $ 0.79 (2.72 %)    

Friday, 03-May-2024 15:59:23 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 29.79
$ 30.05
$ 0.00 x 0
$ 0.00 x 0
$ 29.45 - $ 30.28
$ 25.60 - $ 77.60
271,442
na
664.79M
$ 0.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 03-10-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-29-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-minerva-surgical-shares-are-trading-higher-by-166-here-are-26-stocks-moving-premarket
Why Minerva Surgical Shares Are Trading Hi...
12/28/2022 12:54:47

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 166% to $0.4327 in pre-market trading after the company reported a...

disc-medicine-receives-fda-orphan-drug-designation-for-bitopertin-for-treatment-of-erythropoietic-protoporphyria
Disc Medicine Receives FDA Orphan Drug Des...
12/27/2022 13:02:43

gemini-therapeutics-merger-company-disc-medicine-granted-fda-orphan-designation-for-erythropoietic-protoporphyria-treatment
'Gemini Therapeutics Merger Company Disc M...
12/22/2022 16:53:25

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=916222

gemini-therapeutics-merger-partner-disc-medicine-initiates-aurora-phase-2-clinical-study-of-bitopertin-in-adults-with-erythropoietic-protoporphyria
Gemini Therapeutics Merger Partner Disc Me...
10/31/2022 13:03:44

why-invitae-climbed-around-279-here-are-98-biggest-movers-from-yesterday
Why Invitae Climbed Around 279%; Here Are ...
08/11/2022 09:28:25

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 ...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
08/10/2022 17:55:50

 

biotech-daily-cancer-causing-impurities-in-mercks-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlons-monkeypox-trial
Biotech Daily: Cancer Causing Impurities I...
08/10/2022 15:33:07

Here's a roundup of top developments in the biotech space over the last 24 hours:

gemini-therapeutics-announces-reverse-merger-pact-with-hematology-focused-company
Gemini Therapeutics Announces Reverse Merg...
08/10/2022 13:36:07

gemini-therapeutics-inc-cm-shares-to-resume-trade-at-800-am-et
Gemini Therapeutics, Inc. Cm Shares To Res...
08/10/2022 11:36:06

gemini-therapeutics-and-disc-medicine-announce-merger-agreement
Gemini Therapeutics And Disc Medicine Anno...
08/10/2022 11:31:11

Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of he...

gemini-therapeutics-shares-halted-news-pending
Gemini Therapeutics Shares Halted; News Pe...
08/10/2022 11:26:41

the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy-decision-pushed-protagonists-rusfertide-breakthrough-tag-update-and-more
The Daily Biotech Pulse: Pfizer-BioNTech C...
04/14/2022 13:35:44

Here's a roundup of top developments in the biotech space over the last 24 hours:

gemini-therapeutics-director-michael-leonard-buys-955k-shares-at-average-price-of-140share
Gemini Therapeutics Director Michael Leona...
04/13/2022 20:13:43

-SEC Filing

benzingas-top-ratings-upgrades-downgrades-for-march-11-2022
Benzinga's Top Ratings Upgrades, Downgrade...
03/11/2022 15:28:32

Upgrades

10-biggest-price-target-changes-for-friday
10 Biggest Price Target Changes For Friday
03/11/2022 11:49:42

Needham cut the price target on OppFi Inc. (NYSE: OPFI) from $10 to $4.5. OppFi shares rose 5.3% to $3.20 in pre-market tra...

hc-wainwright--co-downgrades-gemini-therapeutics-to-neutral-lowers-price-target-to-2
HC Wainwright & Co. Downgrades Gemini Ther...
03/11/2022 11:46:41

HC Wainwright & Co. analyst Andrew Fein downgrades Gemini Therapeutics (NASDAQ:GMTX) from Buy to Neutral and lowers the ...

gemini-therapeutics-fy21-net-loss-719m-vs-loss-408m-in-fy20
Gemini Therapeutics FY21 Net Loss $71.9M v...
03/10/2022 12:14:14

what-5-analyst-ratings-have-to-say-about-gemini-therapeutics
What 5 Analyst Ratings Have To Say About G...
03/03/2022 21:03:00

Within the last quarter, Gemini Therapeutics (NASDAQ:GMTX) has observed the following analyst ratings:

benzingas-top-ratings-upgrades-downgrades-for-march-3-2022
Benzinga's Top Ratings Upgrades, Downgrade...
03/03/2022 15:03:30

Upgrades

10-biggest-price-target-changes-for-thursday
10 Biggest Price Target Changes For Thursday
03/03/2022 11:53:42

Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION